Status:
COMPLETED
The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension
Lead Sponsor:
Gulhane School of Medicine
Conditions:
Diabetes
Hypertension
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Diabetic nephropathy (DN) is the most important complication of diabetes mellitus (DM) and the most common cause of end-stage renal disease (ESRD). Diabetic nephropathy is a clinical syndrome characte...
Detailed Description
The patients who were non-obese (BMI\<30kg/m2), non dyslipidemic (total cholesterol \<200mg/dl, Triglyceride\<150mg/dl), and free of cardiovascular events (negative medical history, negative ECG findi...
Eligibility Criteria
Inclusion
- CKD stage 1 patients
- Older than 18 years of age
- Type 2 Diabetic patients
- Proteinuria
- Hypertension
Exclusion
- History of coronary artery disease
- Smokers
- Taking statins or renin-angiotensin blockers
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT00921570
Start Date
February 1 2008
End Date
May 1 2009
Last Update
June 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GATA Nephrology
Ankara, Turkey (Türkiye), 06108